Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05344469
Other study ID # COMB157GDE02
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 10, 2022
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable Disease-modifying Therapy (DMT) for Relapsing Multiple Sclerosis in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to approx. two years of treatment. Additionally, medical history of participants will be collected including disease duration, EDSS, MRI parameters and relapses.


Description:

The prerequisite for participation in this observational study is the independent decision of the treating physician and patient to start an approved injectable DMT for RMS as routine medical treatment. This decision must have been made prior to enrollment in this study. The prospective observational period per patient will be up to approx. two years from the time of consent (2 years +2 months visit window). The observational period will not be dictated by the protocol. The follow-up documentation will take place at a frequency defined as per investigator's discretion. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care, can be performed as telemedicine visits and will take place as per investigator's discretion.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study 2. Male or female patients aged =18 years at enrollment 3. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b) 4. RMS with active disease as defined by Lublin et al. (2014) 5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment 6. Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive) 7. Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment Exclusion Criteria: 1. Patients being treated outside of the approved label 2. > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment 3. Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7) 4. Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy 5. Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator 6. EDSS Functional System Score "Pyramidal Functions" = 2 at enrollment 7. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab

Study Design


Intervention

Other:
ofatumumab
There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
glatiramer acetate
There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
interferon ß1
There is no treatment allocation. Patients administered interferon ß1 by prescription that have started as routine medical treatment will be enrolled.

Locations

Country Name City State
Germany Novartis Investigative Site Altenburg
Germany Novartis Investigative Site Altenholz
Germany Novartis Investigative Site Altmark Sachsen-Anhalt
Germany Novartis Investigative Site Alzey
Germany Novartis Investigative Site Bad Homburg
Germany Novartis Investigative Site Bamberg
Germany Novartis Investigative Site Bamberg Bavaria
Germany Novartis Investigative Site Bayreuth
Germany Novartis Investigative Site Bergneustadt
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Boblingen
Germany Novartis Investigative Site Bochum
Germany Novartis Investigative Site Bochum
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Bremen
Germany Novartis Investigative Site Chemnitz
Germany Novartis Investigative Site Dessau
Germany Novartis Investigative Site Dillingen
Germany Novartis Investigative Site Dortmund
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Duesseldorf
Germany Novartis Investigative Site Duisburg
Germany Novartis Investigative Site Düsseldorf
Germany Novartis Investigative Site Düsseldorf
Germany Novartis Investigative Site Erbach
Germany Novartis Investigative Site Erfurt
Germany Novartis Investigative Site Erlangen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Essen Nordrhein-Westfalen
Germany Novartis Investigative Site Falkensee Brandenburg
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Fulda
Germany Novartis Investigative Site Gelsenkirchen
Germany Novartis Investigative Site Giessen
Germany Novartis Investigative Site Gladenbach
Germany Novartis Investigative Site Hagen
Germany Novartis Investigative Site Halle (Saale)
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Hannover Lower Saxony
Germany Novartis Investigative Site Hannover Lower Saxony
Germany Novartis Investigative Site Hettingen Baden Wuerttemberg
Germany Novartis Investigative Site Ingelheim
Germany Novartis Investigative Site Itzehoe
Germany Novartis Investigative Site Jena
Germany Novartis Investigative Site Kaiserslautern
Germany Novartis Investigative Site Koln
Germany Novartis Investigative Site Köln
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Luenen
Germany Novartis Investigative Site Mannheim
Germany Novartis Investigative Site Marburg
Germany Novartis Investigative Site Marburg
Germany Novartis Investigative Site Meerbusch North Rhine-Westfalia
Germany Novartis Investigative Site Mettmann
Germany Novartis Investigative Site Minden
Germany Novartis Investigative Site Muelheim an der Ruhr
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenster
Germany Novartis Investigative Site Muenster Northwest
Germany Novartis Investigative Site Mühlhausen
Germany Novartis Investigative Site München
Germany Novartis Investigative Site Munich Bavaria
Germany Novartis Investigative Site Nagold
Germany Novartis Investigative Site Neuburg an der Donau
Germany Novartis Investigative Site Neuruppin
Germany Novartis Investigative Site Nuernberg
Germany Novartis Investigative Site Oer-Erkenschwick Northrhine Westfalia
Germany Novartis Investigative Site Osnabrück
Germany Novartis Investigative Site Pforzheim
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Regensburg
Germany Novartis Investigative Site Remscheid
Germany Novartis Investigative Site Rostock
Germany Novartis Investigative Site Ruedersdorf
Germany Novartis Investigative Site Ruelzheim
Germany Novartis Investigative Site Saalouis
Germany Novartis Investigative Site Schwaebisch Baden-Wuerttemberg
Germany Novartis Investigative Site Schwetzingen BW
Germany Novartis Investigative Site Siegen
Germany Novartis Investigative Site Stadtroda
Germany Novartis Investigative Site Stuttgart
Germany Novartis Investigative Site Stuttgart
Germany Novartis Investigative Site Stuttgart
Germany Novartis Investigative Site Trier
Germany Novartis Investigative Site Tuebingen
Germany Novartis Investigative Site Unterhaching
Germany Novartis Investigative Site Untermeiting Bayern
Germany Novartis Investigative Site Weil der Stadt
Germany Novartis Investigative Site Wildeshausen Lower Saxony
Germany Novartis Investigative Site Wolfratshausen

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who continue to receive their first-line treatment Proportion of patients who continue to receive their first-line treatment (ofatumumab or injectable SOC therapies (IFN-ß1 or GA)) Month 24
Secondary Proportion of patients who continue to receive their first-line treatment Proportion of patients who continue to receive their first-line treatment (ofatumumab or injectable SOC therapies (IFN-ß1 or GA)) Month 12
Secondary Impact of first-line treatment on health economy Mean annual health care resource utilization cost, annual direct medical costs, annual direct nonmedical costs and annual indirect costs as measured by MS Health Resource Utilization Survey [MS-HRS]
MS-HRS is a 24-item questionnaire covers societal resource use, regardless of the issue of reimbursement, as well as impact of the disease on work, family and leisure. With the help of this questionnaire a monetary value can be assigned to e.g. the stage of MS, a relapse or a therapy.
Baseline, month 6, month 12, month 18 and month 24
Secondary Fatigue Symptoms and Impact Questionnaire-RMS Fatigue Symptoms and Impact Questionnaire-RMS [FSIQ-RMS]
The FSIQ-RMS comprises 20 items organized in a conceptual framework with 2 symptom domains (energy, muscle weakness) and 7 impact domains (daily activities, cognition, emotions, physical impact, self-care, sleep, social impact) in order to measure fatigue symptoms and impacts in relapsing multiple sclerosis.
A scoring algorithm standardizes scores on both the symptoms domain (daily and weekly) and impacts subdomains (weekly) to a 0 to 100 scale, with higher scores indicating more severe symptoms and impacts. There is no single summary score across the FSIQ-RMS instrument, but rather 1 symptoms score and 3 impacts subdomain scores.
Baseline, month 3, month 6, month 12, month 18, month 24
Secondary Patient Health Questionnaire 8 [PHQ-8] The PHQ-8 is a valid diagnostic and severity measure for depressive disorders. It consists of eight items, each of which is scored 0 to 3, providing a 0 to 24 severity score. Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively. Baseline, month 3, month 6, month 12, month 18, month 24
Secondary Generalized Anxiety Disorder Scale 7 [GAD-7] The GAD-7 is a validated 7-item anxiety scale to diagnose generalized anxiety disorder. Each of the items is scored 0 to 3, providing a 0 to 21 severity score. Scores of 5, 10, and 15 represent cutpoints for mild, moderate, and severe anxiety, respectively Baseline, month 3, month 6, month 12, month 18, month 24
Secondary MS Treatment Concerns Questionnaire [MSTCQ] MS Treatment Concerns Questionnaire [MSTCQ] is used to assess participants' satisfaction with their treatment injections.
The MSTCQ includes 20 items pertaining satisfaction with the injection system (including issues related to use of the device and preparation of the medication for injection), and AEs related to the patient MS treatment.
All questions have a 5-point response choice, with the responses scored between 1-5. The MSTCQ scores are formed as the sum of all scores. The maximum total score is 100. Lower scores indicate a better state.
Baseline, month 3, month 6, month 12, month 18, month 24
Secondary Expanded disability status scale (EDSS) EDSS is a widely used and accepted instrument to evaluate disability status at a given time and, longitudinally, to assess accumulation of disability in clinical studies in MS. The EDSS scale consists of scores in each of seven functional systems (FSs) and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The FSs are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, and Cerebral functions (Fatigue contributes) Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Time to onset of confirmed disability progression (CDP) Time to onset of confirmed disability progression (CDP) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Proportion of patients with confirmed disability progression (CDP) Proportion of patients with confirmed disability progression (CDP) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Time to onset of confirmed disability improvement (CDI) Time to onset of confirmed disability improvement (CDI) defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Proportion of patients with CDI Proportion of patients with CDI defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary T1 Gd-enhancing lesions per brain T1 Gd-enhancing lesions per brain to be measured Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Annualized T2 lesion rate New or enlarging T2 lesions per brain and per year (annualized T2 lesion rate) Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator. Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator. NEDA3 is defined as no 3mCDP, no confirmed MS relapse and no new or enlarging T2 lesions on any MRI scan compared to baseline Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Secondary Proportion of patients with no clinical disease activity and no discontinuation of current treatment due to AEs Proportion of patients with no clinical disease activity measured by relapse and disease progression and no discontinuation of current treatment due to AEs (excluding pregnancies) and lack of effectiveness Up to 24 months
Secondary Annualized relapse rate Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year.
Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.
Up to 24 months
Secondary Time to first relapse Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection. Up to 24 months
Secondary Proportion of relapse free patients Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection. Up to 24 months
Secondary Number of patients and reasons for discontinuation of treatment Number of patients and reasons for discontinuation of treatment classified by category:
efficacy (e.g. occurrence of relapse, evidence of disease activity in MRI)
safety and tolerability (e.g. injection-site reactions, influenza-like symptoms)
or convenience (e.g. inconvenient administration, frequency of injections)
Up to 24 months
Secondary Proportion of patients who continue to receive their subsequent treatment Proportion of patients who, at a given time over the period of 2 years, continue to receive their subsequent treatment Up to 24 months
Secondary Reasons for and number of treatment interruptions per patient Reasons for and number of treatment interruptions per patient to be collected Up to 24 months
Secondary Duration of treatment interruptions per patient Duration of treatment interruptions per patient to be collected Up to 24 months
Secondary Number of patients with treatment interruptions Number of patients with treatment interruptions to be collected Up to 24 months
Secondary Proportion of drug-related adverse events (AEs) Proportion of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions) Up to 24 months
Secondary Persistence of drug-related adverse events (AEs) Persistence of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions, influenza-like symptoms) Up to 24 months
Secondary Specific safety assessment of injection related AEs Specific safety assessment of injection related AEs. (i.e. injection site reaction AEs vs. injection systemic reaction AEs) summarized by providing the number and percentage of patients with each of the symptoms and pre-specified grouping of symptoms as well as overall. Up to 24 months
Secondary Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons Up to 24 months
Secondary Presence of spinal cord lesions Proportion of patients with spinal cord lesions present Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24
See also
  Status Clinical Trial Phase
Recruiting NCT04121065 - Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
Active, not recruiting NCT03996291 - Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis Phase 2
Recruiting NCT04510220 - 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis Phase 3
Terminated NCT02241785 - Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies Phase 4
Completed NCT02792218 - Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Phase 3
Completed NCT01412333 - A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Phase 3
Completed NCT03257358 - A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Phase 4
Completed NCT01628393 - Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Phase 2/Phase 3
Completed NCT04626921 - A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis Phase 2/Phase 3
Withdrawn NCT02234869 - Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy Phase 4
Withdrawn NCT05077956 - Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
Active, not recruiting NCT04486716 - A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis Phase 3
Recruiting NCT04121403 - Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Phase 3
Recruiting NCT05809986 - Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Terminated NCT00988052 - A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course Phase 3
Active, not recruiting NCT05232825 - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Phase 3
Terminated NCT01047319 - A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis Phase 3
Completed NCT04847596 - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Completed NCT01006941 - Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study Phase 2
Completed NCT01127750 - Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients Phase 3